Abstract
Introduction: Congenital hypothyroidism (CH), the most common neonatal endocrine disorder worldwide, can be caused by variants in the thyroid peroxidase (TPO) gene. This study aimed to identify TPO variants in Chinese patients with CH, analyze their impact on TPO function, and establish relationships between TPO genotypes and clinical characteristics. Methods: A total of 328 patients with CH were screened for TPO variants by performing whole-exome sequencing. The function of the detected TPO variants was investigated via transfection assays in vitro. The pathogenic effect of five novel variants was further assessed in silico. Results: Among 328 patients with CH, 19 TPO variants, including six novel ones, were identified in 43 patients. Eighteen patients (5.5%) carried biallelic TPO variants. In vitro experiments showed that TPO activity was impaired to varying degrees in 17 variants. Furthermore, we determined that a residual TPO enzyme activity threshold of 15% may serve as a criterion for differentiating CH severity. Conclusions: According to our study, the prevalence of TPO variants among Chinese patients with CH was 13.1%. Five novel variants led to impaired TPO function by altering its structure or by affecting its expression or cellular localization, which should result in impaired thyroid hormone synthesis.
Journal Section:
Research Article
References
1.
van Trotsenburg P, Stoupa A, Léger J, Rohrer T, Peters C, Fugazzola L, et al. Congenital hypothyroidism: a 2020–2021 consensus guidelines update-an ENDO-European reference network initiative endorsed by the European society for pediatric endocrinology and the European society for endocrinology. Thyroid. 2021;31(3):387–419.
2.
Gu X, Wang Z, Ye J, Han L, Qiu W. Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening. Ann Acad Med Singap. 2008;37(12 Suppl):107–4.
3.
Kibirige MS, Hutchison S, Owen CJ, Delves HT. Prevalence of maternal dietary iodine insufficiency in the north east of England: Implications for the fetus. Arch Dis Child Fetal Neonatal Ed. 2004;89(5):F436–9.
4.
Kostopoulou E, Miliordos K, Spiliotis B. Genetics of primary congenital hypothyroidism-a review. Hormones (Athens). 2021;20(2):225–36.
5.
Sun F, Zhang JX, Yang CY, Gao GQ, Zhu WB, Han B, et al. The genetic characteristics of congenital hypothyroidism in China by comprehensive screening of 21 candidate genes. Eur J Endocrinol. 2018;178(6):623–33.
6.
Zhang RJ, Yang GL, Cheng F, Sun F, Fang Y, Zhang CX, et al. The mutation screening in candidate genes related to thyroid dysgenesis by targeted next-generation sequencing panel in the Chinese congenital hypothyroidism. Clin Endocrinol. 2022;96(4):617–26.
7.
Wang F, Xiaole L, Ma R, Zhao D, Liu S. Dual oxidase system genes defects in children with congenital hypothyroidism. Endocrinology. 2021;162(8):162.
8.
Belforte FS, Miras MB, Olcese MC, Sobrero G, Testa G, Muñoz L, et al. Congenital goitrous hypothyroidism: mutation analysis in the thyroid peroxidase gene. Clin Endocrinol. 2012;76(4):568–76.
9.
Ma SG, Qiu YL, Zhu H, Liu H, Li Q, Ji CM. Novel genetic variants in the TPO gene cause congenital hypothyroidism. Scand J Clin Lab Invest. 2015;75(8):633–7.
10.
Baş VN, Aycan Z, Cangul H, Kendall M, Ağladıoğlu SY, Çetinkaya S, et al. A common thyroid peroxidase gene mutation (G319R) in Turkish patients with congenital hypothyroidism could be due to a founder effect. Journal of Pediatric Endocrinology and Metabolism. J Pediatr Endocrinol Metab. 2014;27(3–4):383–7.
11.
Ris-Stalpers C, Bikker H. Genetics and phenomics of hypothyroidism and goiter due to TPO mutations. Mol Cell Endocrinol. 2010;322(1–2):38–43.
12.
Cangul H, Aycan Z, Olivera-Nappa A, Saglam H, Schoenmakers NA, Boelaert K, et al. Thyroid dyshormonogenesis is mainly caused by TPO mutations in consanguineous community. Clin Endocrinol. 2013;79(2):275–81.
13.
Nilsson M, Fagman H. Development of the thyroid gland. Development. 2017;144(12):2123–40.
14.
Carvalho DP, Dupuy C. Role of the NADPH oxidases DUOX and NOX4 in thyroid oxidative stress. Eur Thyroid J. 2013;2(3):160–7.
15.
Williams DE, Le SN, Godlewska M, Hoke DE, Buckle AM. Thyroid peroxidase as an autoantigen in hashimoto’s disease: structure, function, and antigenicity. Horm Metab Res. 2018;50(12):908–21.
16.
Rivolta CM, Esperante SA, Gruneiro-Papendieck L, Chiesa A, Moya CM, Domene S, et al. Five novel inactivating mutations in the thyroid peroxidase gene responsible for congenital goiter and iodide organification defect. Hum Mutat. 2003;22(3):259.
17.
Zhang J, Han R, Shen L, Xie J, Xiao Y, Jiang L, et al. Mild TPO deficiency characterized by progressive goiter and normal serum TSH level. Endocrine. 2020;68(3):599–606.
18.
Avbelj M, Tahirovic H, Debeljak M, Kusekova M, Toromanovic A, Krzisnik C, et al. High prevalence of thyroid peroxidase gene mutations in patients with thyroid dyshormonogenesis. Eur J Endocrinol. 2007;156(5):511–9.
19.
Niu DM, Hwang B, Chu YK, Liao CJ, Wang PL, Lin CY. High prevalence of a novel mutation (2268 insT) of the thyroid peroxidase gene in Taiwanese patients with total iodide organification defect, and evidence for a founder effect. J Clin Endocrinol Metab. 2002;87(9):4208–12.
20.
Zhang RJ, Sun F, Chen F, Fang Y, Yan CY, Zhang CR, et al. The TPO mutation screening and genotype-phenotype analysis in 230 Chinese patients with congenital hypothyroidism. Mol Cell Endocrinol. 2020;506:110761.
21.
Bauer AJ, Wassner AJ. Thyroid hormone therapy in congenital hypothyroidism and pediatric hypothyroidism. Endocrine. 2019;66(1):51–62.
22.
Yang RM, Zhan M, Zhou QY, Ye XP, Wu FY, Dong M, et al. Upregulation of GBP1 in thyroid primordium is required for developmental thyroid morphogenesis. Genet Med. 2021;23(10):1944–51.
23.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9.
24.
Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575–6.
25.
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–81.
26.
Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet. 2016;48(12):1581–6.
27.
Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877–85.
28.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–24.
29.
Lee CC, Harun F, Jalaludin MY, Heh CH, Othman R, Junit SM. Prevalence of c.2268dup and detection of two novel alterations, c.670_672del and c.1186C[{GT}]T, in the TPO gene in a cohort of Malaysian-Chinese with thyroid dyshormonogenesis. BMJ Open. 2015:5(1):e006121.
30.
Ozbek MN, Uslu AB, Onenli-Mungan N, Yuksel B, Pohlenz J, Topaloglu AK. Thyroid peroxidase gene mutations causing congenital hypothyroidism in three Turkish families. J Pediatr Endocrinol Metab. 2009;22(11):1033–39.
31.
Yoshizawa-Ogasawara Atsuko, Abe Kiyomi, Ogikubo Sayaka, Narumi Satoshi, Hasegawa Tomonobu, Satoh Mari. Transient congenital hypothyroidism caused by compound heterozygous mutations affecting the NADPH-oxidase domain of DUOX2. J Pediatr Endocrinol Metab2191-0251. 2016;29(3):363–71. 26565538.
32.
Rivolta CM, Louis-Tisserand M, Varela V, Gruñeiro-Papendieck L, Chiesa A, González-Sarmiento R, et al. Two compound heterozygous mutations (c.215delA/c.2422T--[{GT}]C and c.387delC/c.1159G--[{GT}]A) in the thyroid peroxidase gene responsible for congenital goitre and iodide organification defect. Clin Endocrinol. 2007;67(2):238–46.
33.
Bruellman RJ, Watanabe Y, Ebrhim RS, Creech MK, Abdullah MA, Dumitrescu AM, et al. Increased prevalence of TG and TPO mutations in sudanese children With congenital hypothyroidism. J Clin Endocrinol Metab. 2020;105(5):1564–72.
34.
de Filippis T, Gelmini G, Paraboschi E, Vigone MC, Di Frenna M, Marelli F, et al. A frequent oligogenic involvement in congenital hypothyroidism. Hum Mol Genet. 2017;26(13):2507–14.
35.
Long W, Lu G, Zhou W, Yang Y, Zhang B, Zhou H, et al. Targeted next-generation sequencing of thirteen causative genes in Chinese patients with congenital hypothyroidism. Endocr J. 2018;65(10):1019–28.
36.
Bikker H, Vulsma T, Baas F, de Vijlder JJ. Identification of five novel inactivating mutations in the human thyroid peroxidase gene by denaturing gradient gel electrophoresis. Hum Mutat. 1995;6(1):9–16.
37.
Bakker B, Bikker H, Vulsma T, de Randamie JS, Wiedijk BM, De Vijlder JJ. Two decades of screening for congenital hypothyroidism in The Netherlands: TPO gene mutations in total iodide organification defects (an update). J Clin Endocrinol Metab. 2000;85(10):3708–12.
38.
Yamaguchi T, Nakamura A, Nakayama K, Hishimura N, Morikawa S, Ishizu K, et al. Targeted next-generation sequencing for congenital hypothyroidism with positive neonatal TSH screening. J Clin Endocrinol Metab. 2020;105(8).
39.
Umeki K, Yamamoto I, Yukizane S, Kotani T. Congenital hypothyroidism caused by a unique thyroid peroxidase allele containing two mutations, C1708T and C2737T. J Pediatr Endocrinol Metab. 2004;17(2):231–4.
40.
Brnich SE, Abou Tayoun AN, Couch FJ, Cutting GR, Greenblatt MS, Heinen CD, et al., Clinical Genome Resource Sequence Variant Interpretation Working Group. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med. 2019;12(1):3.
41.
Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr. 2014;81(2):80–103.
42.
Godlewska M, Góra M, Buckle AM, Porebski BT, Kemp EH, Sutton BJ, et al. A redundant role of human thyroid peroxidase propeptide for cellular, enzymatic, and immunological activity. Thyroid. 2014;24(2):371–82.
43.
Abramowicz MJ, Targovnik HM, Varela V, Cochaux P, Krawiec L, Pisarev MA, et al. Identification of a mutation in the coding sequence of the human thyroid peroxidase gene causing congenital goiter. J Clin Invest. 1992;90(4):1200–4.
44.
Löf C, Patyra K, Kuulasmaa T, Vangipurapu J, Undeutsch H, Jaeschke H, et al. Detection of novel gene variants associated with congenital hypothyroidism in a Finnish patient cohort. Thyroid. 2016;26(9):1215–24.
45.
Narumi S, Muroya K, Asakura Y, Aachi M, Hasegawa T. Molecular basis of thyroid dyshormonogenesis: genetic screening in population-based Japanese patients. J Clin Endocrinol Metab. 2011;96(11):E1838–42.
46.
Chen X, Kong X, Zhu J, Zhang T, Li Y, Ding G, et al. Mutational spectrum analysis of seven genes associated with thyroid dyshormonogenesis. Int J Endocrinol. 2018;2018:8986475.
47.
Fu C, Xie B, Zhang S, Wang J, Luo S, Zheng H, et al. Mutation screening of the TPO gene in a cohort of 192 Chinese patients with congenital hypothyroidism. BMJ Open. 2016:6(5):e010719.
48.
Lee ST, Lee DH, Kim JY, Kwon MJ, Kim JW, Hong YH, et al. Molecular screening of the TSH receptor (TSHR) and thyroid peroxidase (TPO) genes in Korean patients with nonsyndromic congenital hypothyroidism. Clin Endocrinol. 2011;75(5):715–21.
49.
Targovnik HM, Scheps KG, Rivolta CM. Defects in protein folding in congenital hypothyroidism. Mol Cell Endocrinol. 2020;501:110638.
50.
Wu JY, Shu SG, Yang CF, Lee CC, Tsai FJ. Mutation analysis of thyroid peroxidase gene in Chinese patients with total iodide organification defect: identification of five novel mutations. J Endocrinol. 2002;172(3):627–35.
51.
Victorio CG, Sawyer N. Folding-Assisted Peptide Disulfide Formation and Dimerization. ACS Chem biol. 2023;18(7):1480–6.
52.
Bikker H, Baas F, De Vijlder JJ. Molecular analysis of mutated thyroid peroxidase detected in patients with total iodide organification defects. J Clin Endocrinol Metab. 1997;82(2):649–53.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
